Mankind Pharma Limited — PPTs, 21-05-2025: Investor Presentation

1. Financial Highlights:

Mankind Pharma’s revenue rose 27% YoY in Q4FY25 to INR 3,079 Cr and 19% for FY25 to INR 12,207 Cr. Adjusted EBITDA margins were ~23% in Q4 and ~26% for the year, with EBITDA of INR 686 Cr (Q4) and INR 3,030 Cr (FY25). PAT declined 10% YoY to INR 429 Cr in Q4 but grew 3.4% to INR 2,007 Cr for FY25. Gross margin improved by 190 bps to 71.6%. Return on capital employed (ROCE) remained strong at 40%, with net debt/EBITDA at 1.8x. Domestic sales formed 83% of revenue, consumer healthcare grew 15% to INR 809 Cr, while exports nearly doubled to INR 1,532 Cr.

2. Strategic Initiatives & Growth Drivers:

Focus remains on four pillars: base business, specialty chronic therapies (cardio, diabetes, CNS), OTC/consumer healthcare, and BSV’s super specialty portfolio. Successful launches include Empagliflozin, Inclisiran, and Vonoprazan. Consumer healthcare was spun off into a subsidiary to accelerate growth. The company is expanding specialty divisions, boosting R&D, and employing AI/ML to enhance operational efficiency.

3. Business Developments:

Integration of BSV strengthened specialty presence, with mandate brands growing 18%; key product launches include insulin glargine and inhalers. Expanded specialty portfolio via in-licensing agreements with Novartis, AstraZeneca, Takeda, and acquisition of oncology/transplant brands from Panacea Biotec. Export revenue doubled, supported by new products and geographic expansion.

4. Market Position & Competitive Advantage:

Mankind’s market share rose to 4.8%. It leads prescriptions for eight years running and is #2 by volume in India’s pharma market. The company outpaced IPM growth with 1.3x expansion in chronic segments and holds strong positions across cardio, anti-diabetic, gynecology, and gastro therapies. Its wide brand base, large sales force (18,000+), and extensive distributor network (13,000+ stockists) provide competitive scale advantages domestically and internationally.

5. Investor Implications:

Diverse portfolio, strong market coverage, and BSV integration offer promising growth potential. Continued specialty and consumer healthcare focus, alongside digital initiatives, support margin and top-line expansion. Execution risks around integration and competition remain, but steady growth driven by specialty and export segments is expected.